NCT03301181View on ClinicalTrials.gov

Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 18, 2017

Primary Completion Date

November 7, 2017

Study Completion Date

November 13, 2017

Conditions
Healthy Volunteers: Asian, Non-Asian
Interventions
DRUG

BGB-3111 (Arm A)

320 mg BGB-3111 single oral dose

DRUG

Rifampin

600 mg rifampin once daily

DRUG

BGB-3111 (Arm B)

Up to 80 mg BGB-3111 single oral dose

DRUG

Itraconazole

200 mg itraconazole once daily

Trial Locations (1)

90630

West Coast Clinical Trials (WCCT), Cypress

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT03301181 - Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects | Biotech Hunter | Biotech Hunter